For most HCC patients, the PD-1/PD-L1 pathway is not the only limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response. Here, CD274 is linked to hepatocellular carcinoma.